Atlas Venture reports in its 2022 Year in Review, there are "7000 drugs in clinical development around the world, supported by $200B of R&D spend". With R&D being the lifeline of many biopharma companies, companies are feeling the pressure to get more done with capital already raised against a backdrop of a volatile economic environment and uncertain capital market. What strategies are companies deploying to keep foundational R&D progressing? How are executive teams managing CROs? Are there opportunities for CROs to demonstrate better alignment with the rising costs and a tougher funding environment challenging biopharma companies?